Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Eli Lilly and : Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 05:33pm CET

LEAWOOD, Kan., Nov. 10, 2017 /PRNewswire/ -- Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. (NASDAQ: PETX), today announced the European Medicine Agency's (EMA) Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion to recommend the marketing authorization of GALLIPRANT(®) (grapiprant tablets) in the European Union. Following the positive opinion, the European Commission will complete the regulatory process for a final decision on the Marketing Authorisation in early 2018.

Galliprant is a first-in-class veterinary medicine that will be indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Grapiprant, the active ingredient in Galliprant, is a non-steroidal non-cyclooxygenase inhibiting anti-inflammatory drug. Elanco has exclusive rights to develop, manufacture, market and commercialize Galliprant globally, and it co-promotes the product with Aratana in the United States.

About Elanco Animal Health
Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 70 countries around the world. We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 6,500 employees worldwide. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Founded in 1954, Elanco is a division of Eli Lilly and Company. Our worldwide headquarters and research facilities are located in Greenfield, Indiana (U.S.). Visit us at www.elanco.com or www.elancoeurope.com.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Galliprant, and reflects Lilly, Elanco's and Aratana's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Galliprant will be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's and Aratana's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission, respectively. Except as required by law, Elanco and Aratana undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Media Contacts
Karin Gerbens
[email protected]
+32 476 978 467

Rachel Reiff
[email protected]
+1 (913) 353-1050

View original content:http://www.prnewswire.com/news-releases/elanco-aratana-announce-positive-opinion-on-galliprant-grapiprant-tablets-in-europe-300553682.html

SOURCE Aratana Therapeutics, Inc.

© PRNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
01/17 Keytruda meets OS, PFS endpoints in first-line NSCLC
01/15 ELI LILLY AND : Research Isn’t Just Science
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/11 ELI LILLY AND : Lilly to Present at J.P. Morgan Healthcare Conference
01/11 ELI LILLY AND : Studies from Eli Lilly and Company Add New Findings in the Area ..
01/11 ELI LILLY AND : Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® ..
01/10 ELI LILLY AND : Taking a Closer Look at Access to New Medicines
01/10 ELI LILLY AND : How Art Can Spark a Movement in Clinical Research Awareness
01/10 ELI LILLY AND : Azar vows to lower list prices
01/09 BOSTON SCIENTIFIC : Health Care Up On Earnings Optimism -- Health Care Roundup
More news
News from SeekingAlpha
01/17 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Merck's Keytruda Rises, Celgene's Possibl..
01/16 FDA launches new program to boost transparency of clinical data used to suppo..
01/16 Premarket analyst action - healthcare
01/16 2018 STRATEGIC OUTLOOK : Will Fortune Favor The Bold In Biotech?
01/16 Merck's Keytruda successful in first-line lung cancer study; shares up 1% pre..